# Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Canonical URL: https://biopharmsignal.com/news/OTLK/outlook-therapeutics-wins-appeal-following-formal-dispute-resolution-process-for-ons-5010-lytenavatm-bevacizumab-vikg
Ticker: OTLK
Company: Outlook
Source: Outlook
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.outlooktherapeutics.com
## Summary

Company plans to resubmit BLA to the FDA in June 2026 ISELIN, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment

## Article Body
Company plans to resubmit BLA to the FDA in June 2026 ISELIN, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment
## Recent Company News
- 2026-06-25 13:46 EST — [Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-fda-acceptance-of-resubmitted-biologics-license-application-for-ons-5010-lytenavatm-bevacizumab-vikg-as-a-treatment-for-wet-amd) — Source: Outlook
- 2026-06-25 13:46 EST — [Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-resubmission-of-biologics-license-application-to-u-s-fda-for-ons-5010-lytenavatm-bevacizumab-vikg) — Source: Outlook
- 2026-06-25 13:46 EST — [Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-pricing-of-5-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules) — Source: Outlook
- 2026-06-25 13:46 EST — [Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-wins-appeal-following-formal-dispute-resolution-process-for-ons-5010-lytenavatm-bevacizumab-vikg) — Source: Outlook
- 2026-06-25 13:46 EST — [Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-reports-second-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update) — Source: Outlook
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)